Publications in: “00/09/2018”

Laboratory assay of ADAMS 13

ADAMS 13 is a metalloprotease responsible for cleavage of Von Willebrand ultra large multimers. Severe deficiency of this protease, either by auto-antibodies against it or by complement lead to severe thrombotic diseases, such as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome. There are some evidences that less blatant deficiencies of this protease can play a role in other thrombotic diseases, e.g., ischemic stroke and coronary artery disease. The assay of ADAMS13 is usually unavailable at clinical laboratories, and can be […]

Reducing hospital toxicity: impact on patient outcomes

Circadian rhythms are disrupted by routine hospital care. There is also a loss of personal control of health. This loss can lead to adverse outcomes. The authors evaluated 3,425 consecutive patients admitted to a medical-surgical unit with a control wing (n=2,240) and an intervention wing (n=2,240) over a 2.5 year period. Efforts were made among intervention patients for not disturbing their sleep by reducing nighttime noise, delay of routine phlebotomy to more convenient times (not at 4 AM), monitoring of […]